Xeris Biopharma Holdings, Inc. $XERS Shares Bought by Russell Investments Group Ltd.

Key Points

• Russell Investments Group Ltd. increased its stake in Xeris Biopharma by 632.7% during Q1, purchasing 113,713 additional shares to bring its total ownership to 131,687 shares, valued at approximately $723,000.
• Several institutional investors, including Wells Fargo and Barclays, have also raised their stakes in Xeris Biopharma, indicating growing interest in the company's performance.
• Xeris Biopharma recently reported better-than-expected earnings, posting a loss of just ($0.01) EPS against a consensus estimate of ($0.03), with revenue of $67.71 million surpassing analyst forecasts.

Russell Investments Group Ltd. raised its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 632.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 131,687 shares of the company's stock after acquiring an additional 113,713 shares during the period. Russell Investments Group Ltd. owned approximately 0.08% of Xeris Biopharma worth $723,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. NewEdge Advisors LLC bought a new stake in shares of Xeris Biopharma in the 4th quarter worth $34,000. Apella Capital LLC purchased a new position in Xeris Biopharma in the first quarter worth about $55,000. Xponance Inc. bought a new stake in Xeris Biopharma during the first quarter valued at approximately $57,000. FNY Investment Advisers LLC bought a new position in Xeris Biopharma in the first quarter worth approximately $63,000. Finally, Raymond James Financial Inc. purchased a new position in shares of Xeris Biopharma during the 4th quarter worth $45,000. Institutional investors own 42.75% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on the company. Oppenheimer upped their price target on Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. HC Wainwright initiated coverage on Xeris Biopharma in a research note on Tuesday, August 12th. They issued a "buy" rating and a $10.00 price objective for the company. Wall Street Zen raised Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Finally, Leerink Partners boosted their price target on Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a report on Tuesday, August 19th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $7.08.

Xeris Biopharma Trading Down 0.1%

Shares of XERS traded down $0.01 during trading hours on Thursday, reaching $7.84. 385,409 shares of the company traded hands, compared to its average volume of 2,531,209. The stock's fifty day moving average price is $6.06 and its 200 day moving average price is $5.08. The firm has a market cap of $1.27 billion, a price-to-earnings ratio of -37.45 and a beta of 0.13. Xeris Biopharma Holdings, Inc. has a 12-month low of $2.48 and a 12-month high of $8.03.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02. The company had revenue of $67.71 million for the quarter, compared to the consensus estimate of $64.58 million. On average, research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Insider Transactions at Xeris Biopharma

In other news, Director John Johnson sold 107,500 shares of the stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $7.32, for a total transaction of $786,900.00. Following the transaction, the director owned 833,483 shares of the company's stock, valued at approximately $6,101,095.56. This represents a 11.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kevin Mcculloch bought 25,000 shares of the business's stock in a transaction on Friday, June 13th. The shares were acquired at an average cost of $4.38 per share, for a total transaction of $109,500.00. Following the transaction, the insider directly owned 1,708,585 shares in the company, valued at approximately $7,483,602.30. This trade represents a 1.48% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 192,232 shares of company stock worth $1,430,777 over the last quarter. 4.56% of the stock is owned by corporate insiders.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.